Intercept hits regulatory snag at FDA, likely delaying NASH drug’s approval

Intercept hits regulatory snag at FDA, likely delaying NASH drug’s approval

Source: 
MedCity News
snippet: 

The company said that the agency had requested additional data for obeticholic acid and thus moved the upcoming advisory committee meeting from June 9 to June 26, thereby delaying its decision on approval, which had also been scheduled for June 26.